TG Therapeutics
TG Therapeutics - A Biopharmaceutical Company.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | $250m | Post IPO Debt | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 4301 % | (58 %) | 8290 % | 41 % | 79 % | 41 % | 26 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (5120 %) | (6756 %) | 11 % | 15 % | 23 % | 31 % | 32 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (5204 %) | (7122 %) | 5 % | 7 % | 24 % | 33 % | 36 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 2968 % | 4026 % | 27 % | 29 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
TG Therapeutics is a commercial-stage biopharmaceutical company that acquires, develops, and commercializes treatments for B-cell malignancies and autoimmune diseases. The company's primary focus is on leveraging scientific advances in B-cell biology to develop novel treatments for patients. Its main product is BRIUMVI®, a treatment for relapsing forms of multiple sclerosis (RMS).
TG Therapeutics has a global license agreement with Precision BioSciences for the development and commercialization of Precision's allogeneic CD19 CAR T cell therapy program. The company's business model is focused on the acquisition, development, and commercialization of pharmaceutical products. TG Therapeutics generates revenue through the sale of its approved products.
Keywords: biopharmaceutical, B-cell malignancies, autoimmune diseases, multiple sclerosis, BRIUMVI, CD19 CAR T, drug development, commercialization, licensing agreements, therapeutics
Tech stack
Investments by TG Therapeutics
Edit